Covid-19 Vaccine Candidate 94.5 Percent Effective, Moderna Says
Biotech company Moderna said on Monday that early analysis from its phase 3 trial shows its Covid-19 vaccine is 94.5 percent effective at preventing the infection, offering hope of a second breakthrough in as many weeks. Aired on 11/16/2020.
American pharmaceutical company Moderna announced on Monday that its COVID-19 vaccine candidate is nearly 95% effective. The news comes one week after Pfizer announced its inoculations are also successful. CBS News chief medical correspondent Dr. Jon LaPook has the latest. Moderna said today its coronavirus vaccine is 94.5% effective, similar to early results released by Pfizer last week, making it the second vaccine in the US to have a stunningly high success rate. Noubar Afeyan, Moderna co-founder and chairman, says the company's innovations enable it to "keep the vaccine under refrigeration conditions for up to 30 days," enabling broad distribution. The US drug company Pfizer Inc says its experimental COVID-19 vaccine, developed with German firm BioNTech SE, is more than 90 percent effective in late-stage trials.
The news comes as a major victory in the fight against a pandemic that has killed more than a million people, battered the world's economy, and upended daily life.
Pfizer and BioNTech SE are the first drugmakers to release successful data from a large-scale clinical trial of a COVID-19 vaccine.
More than a billion doses could be administered next year.
BioNTech SE admitted they are still waiting on more results to further prove its safety.
Al Jazeera's Charlie Angela reports. British drug company AstraZeneca and Oxford University say late-stage testing of their Covid-19 vaccine shows it is highly effective.
AstraZeneca says its Covid-19 vaccine is 70 percent effective on average and can be stored at normal fridge temperatures. It is easier to distribute and cheaper than its rivals, making it affordable for the developing world.
Al Jazeera's Jonah Hull reports from London, the United Kingdom.